Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, Truth4Once
Search This Board:
Last Post: 9/19/2014 7:18:11 AM - Followers: 157 - Board type: Free - Posts Today: 1



Probuphine®-This study is enrolling participants by invitation only.

Click For Link To

*As of August 14, 2014 - Approximately 20% enrolled.


Braeburn Pharmaceuticals Identifier:
Information provided by (Responsible Party):
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals

Probuphine Graphic




Continuous Drug Delivery Technology


The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.


Fanapt® (iloperidone)


Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.

Company Overview

Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.


Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] quotations system. For further information please contact


Management Team

Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.


Board of Directors



Strategic Alliances

In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.


Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TTNP News: Current Report Filing (8-k) 09/10/2014 06:01:22 AM
TTNP News: IPOs and Transactions: August 25 - 29 09/02/2014 01:57:00 PM
TTNP News: Securities Registration Statement (s-1) 08/29/2014 11:46:02 AM
TTNP News: Quarterly Report (10-q) 08/13/2014 02:35:21 PM
TTNP News: Current Report Filing (8-k) 07/21/2014 05:13:36 PM
#3640   Yes, got few blocks early in the day Rentier 09/19/14 07:18:11 AM
#3639   Until end of day,, didn't buy any...will matthewverymuch 09/18/14 10:05:08 PM
#3638   You buy any today? The volume flipped Rentier 09/18/14 07:39:29 PM
#3637   Tell you something real crazy, don't even know turks 09/17/14 10:45:27 PM
#3636   oh there is interest here, question is who Rentier 09/17/14 04:29:18 PM
#3635   Know you view dollars versus shares for volume bluejacket6 09/17/14 03:55:18 PM
#3634   Wouldn't surprise me if this trades at cash matthewverymuch 09/17/14 10:46:56 AM
#3633   In with a starter here for long term Mark 09/17/14 09:55:02 AM
#3632   Well...volume is a double-edged sword..obviously...trying to keep in matthewverymuch 09/16/14 11:05:20 PM
#3631   Well you getting the volume you was looking Rentier 09/16/14 09:59:01 PM
#3630   Hard to think positively right now, so probably. matthewverymuch 09/16/14 08:21:06 PM
#3629   So, do you see it breaking the 52-week Rentier 09/16/14 05:09:25 PM
#3628   Your right, nothong has changed, and there actually turks 09/16/14 03:49:16 PM
#3627   If that's the case and it goes lower bluejacket6 09/16/14 12:23:43 PM
#3626   I have my doubts that .58 is the bottom. matthewverymuch 09/16/14 12:00:29 PM
#3625   Think your right, as this bottoms out at bluejacket6 09/16/14 11:40:01 AM
#3624're starting to catch what's going on here. Rentier 09/16/14 11:35:36 AM
#3623   We will see. Playing their games, no other bluejacket6 09/16/14 11:32:02 AM
#3622   Won't get to half million. Truth4Once 09/16/14 11:26:51 AM
#3621   We may rip through a half mil before lunch. bluejacket6 09/16/14 11:11:30 AM
#3620   Going the wrong way, but surprising volume in matthewverymuch 09/16/14 10:36:30 AM
#3619   Young Adults Uninformed About Opioid Abuse Risks Truth4Once 09/13/14 03:25:55 PM
#3618   Well...i wasn't wishing for a huge move, but matthewverymuch 09/12/14 09:34:39 PM
#3617   Tried to warn ya so you wouldn't get Rentier 09/12/14 05:14:17 PM
#3616   So far, sunil reaching out to investors and matthewverymuch 09/12/14 11:13:40 AM
#3615   Gonna need a lawn mower to cut your bluejacket6 09/12/14 11:11:49 AM
#3614   Wake me up when this starts "outperforming"..geez matthewverymuch 09/12/14 11:09:53 AM
#3613   Boy was that short lived. Every time we bluejacket6 09/11/14 02:51:06 PM
#3612   Keep slapping that ask. bluejacket6 09/11/14 12:47:05 PM
#3611   Nice to see a little buying interest here today. bluejacket6 09/11/14 12:21:52 PM
#3610   Agree, with your comments. I doubt they Mark 09/10/14 11:09:38 PM
#3609   They don't necessarily have to raise 18 mill, matthewverymuch 09/10/14 11:05:57 PM
#3608   Your right, I mis-read that, that could be Mark 09/10/14 11:00:41 PM
#3607   Not 18 million shares...up to 18 million dollars matthewverymuch 09/10/14 10:51:28 PM
#3606   It's a shelf is there for when matthewverymuch 09/10/14 10:49:53 PM
#3605   Truth4Once, I see the S1 filing for 18M Mark 09/10/14 10:30:38 PM
#3604   I am waiting long term, as well..however, i matthewverymuch 09/10/14 09:21:17 PM
#3603   You would think. It takes a few days dbg1969 09/10/14 07:30:13 PM
#3602   Lol...some frenzy!!! Our time will come eventually. :) dbg1969 09/10/14 07:25:58 PM
#3601   isn't presenting at a conference supposed to gin Truth4Once 09/10/14 05:05:18 PM
#3600   Maybe i'm wrong, but isn't presenting at a matthewverymuch 09/10/14 04:06:09 PM
#3599   Nothing so far....pretty sad. matthewverymuch 09/10/14 03:27:11 PM
#3598   I wish they would stop trying to put bluejacket6 09/10/14 02:11:23 PM
#3597   Feds step up efforts to combat prescription drug abuse Truth4Once 09/10/14 12:44:56 PM
#3596   This? matthewverymuch 09/10/14 12:44:21 PM
#3595   American Banking and Market news had an article bluejacket6 09/10/14 12:14:18 PM
#3594   Sunil has appeared to whip the crowd into matthewverymuch 09/10/14 10:44:13 AM
#3593   Sunil told me there are going to be matthewverymuch 09/10/14 09:52:55 AM
#3592   9/10/14-Titan Pharmaceuticals to Present at Rodman & Renshaw Truth4Once 09/09/14 10:15:01 PM
#3591   Nice article. Thanks for sharing. It's amazing how dbg1969 09/09/14 09:53:53 PM